Net Cash Provided by (Used in) Financing Activities of Bone Biologics Corp from 31 Oct 2010 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary: Bone Biologics Corp annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Oct 2010 to 31 Dec 2025.
Bone Biologics Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $347,549, a 77% decline year-over-year.
Bone Biologics Corp annual Net Cash Provided by (Used in) Financing Activities for 2025 was $4,700,341, a 6.3% increase from 2024.
Bone Biologics Corp annual Net Cash Provided by (Used in) Financing Activities for 2024 was $4,423,497, a 12% decline from 2023.
Bone Biologics Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $5,044,161, a 14% increase from 2022.
Source SEC data: View on sec.gov

Net Cash Provided by (Used in) Financing Activities, Annual (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Bone Biologics Corp Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$4,700,341	+$276,844	+6.3%	01 Jan 2025	31 Dec 2025	10-K	02 Mar 2026	2025	FY
2024	$4,423,497	-$620,664	-12%	01 Jan 2024	31 Dec 2024	10-K	02 Mar 2026	2025	FY
2023	$5,044,161	+$614,301	+14%	01 Jan 2023	31 Dec 2023	10-K	26 Feb 2025	2024	FY
2022	$4,429,860	-$3,474,091	-44%	01 Jan 2022	31 Dec 2022	10-K	21 Feb 2024	2023	FY
2021	$7,903,951	+$7,501,163	+1862%	01 Jan 2021	31 Dec 2021	10-K	30 Mar 2023	2022	FY
2020	$402,788	-$1,917,212	-83%	01 Jan 2020	31 Dec 2020	10-K	15 Mar 2022	2021	FY
2019	$2,320,000	-$2,049,979	-47%	01 Jan 2019	31 Dec 2019	10-K	15 Apr 2021	2020	FY
2018	$4,369,979	+$969,979	+29%	01 Jan 2018	31 Dec 2018	10-K	30 Mar 2020	2019	FY
2017	$3,400,000	-$3,433,111	-50%	01 Jan 2017	31 Dec 2017	10-K	29 Mar 2019	2018	FY
2016	$6,833,111	+$4,833,111	+242%	01 Jan 2016	31 Dec 2016	10-K	02 Apr 2018	2017	FY
2015	$2,000,000	-$3,390,000	-63%	01 Jan 2015	31 Dec 2015	10-K	30 Mar 2017	2016	FY
2014	$5,390,000	+$4,865,467	+928%	01 Jan 2014	31 Dec 2014	10-K	28 Mar 2016	2015	FY
2013	$524,533	+$517,976	+7900%	01 Jan 2013	31 Dec 2013	10-K	31 Mar 2015	2014	FY
2012	$6,557	+$2,960	+82%	01 Nov 2011	31 Oct 2012	10-K	13 Feb 2014	2013	FY
2011	$3,597	-$2,084	-37%	01 Nov 2010	31 Oct 2011	10-K	29 Jan 2013	2012	FY
2010	$5,681			01 Nov 2009	31 Oct 2010	10-K	30 Jan 2012	2011	FY

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2025	$347,549	-$1,156,927	-77%	01 Jan 2025	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q1 2024	$1,504,476			01 Jan 2024	31 Mar 2024	10-Q	12 May 2025	2025	Q1
Q1 2021	$199,148	+$70,983	+55%	01 Jan 2021	31 Mar 2021	10-Q	13 May 2022	2022	Q1
Q1 2020	$128,165	-$571,835	-82%	01 Jan 2020	31 Mar 2020	10-Q	21 May 2021	2021	Q1
Q1 2019	$700,000	+$200,000	+40%	01 Jan 2019	31 Mar 2019	10-Q	15 Apr 2021	2020	Q1
Q1 2018	$500,000	-$1,500,000	-75%	01 Jan 2018	31 Mar 2018	10-Q	14 May 2019	2019	Q1
Q1 2017	$2,000,000	-$3,633,111	-64%	01 Jan 2017	31 Mar 2017	10-Q	15 May 2018	2018	Q1
Q1 2016	$5,633,111			01 Jan 2016	31 Mar 2016	10-K	02 Apr 2018	2017	FY
Q4 2013	$1,249,000	+$1,249,000		01 Nov 2013	31 Jan 2014	10-Q	17 Mar 2014	2014	Q1
Q4 2012	$0	$0		01 Nov 2012	31 Jan 2013	10-Q	18 Mar 2013	2013	Q1
Q4 2011	$0			01 Nov 2011	31 Jan 2012	10-Q	18 Mar 2013	2013	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.